| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
CHUN-JEN LIU; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:53Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:34:30Z |
Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection
|
Chen L.-T.; Chen M.-F.; Li L.-A.; Lee P.-H.; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:34:06Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-02-02T02:48:15Z |
Compartment theory in Helicobacter pylori-associated gastric carcinogenesis
|
Tseng H.-H.; Hsu P.-I.; Chen H.-C.; Lai K.-H.; Lo G.-H.; Lo C.-C.; Chou N.-H.; Mok K.-T.; Chen I.-S.; Chou N.-H.; Yang H.-B.; Liu L.; PING-NING HSU |
| 臺大學術典藏 |
2020-11-19T03:19:55Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:36Z |
Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection
|
Chen L.-T.;Chen M.-F.;Li L.-A.;Po-Huang Lee;Jeng L.-B.;Lin D.-Y.;Wu C.-C.;Mok K.-T.;Chen C.-L.;Lee W.-C.;Chau G.-Y.;Chen Y.-S.;Lui W.-Y.;Hsiao C.-F.;Whang-Peng J.;Chen P.-J.; Chen L.-T.; Chen M.-F.; Li L.-A.; PO-HUANG LEE; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; Chen P.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:23Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J.; Liu C.-J.; Chang J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B. |
| 臺大學術典藏 |
2020-02-19T09:33:57Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-02-19T09:33:45Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Chen P.-J.; Chang S.S.-C.; Lai K.-L.; Peng C.-Y.; Hu R.-H.; Yu M.-C.; Yang M.-D.; Yang S.-S.; MING-CHIH HO; Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z. |
| 國立成功大學 |
2007 |
Novel heparanase inhibitor PI-88 extends disease free survival in a randomized phase II adjuvant clinical trial in patients with hepatocellular carcinoma (HCC) after curative resection
|
Chen, P. J.; Lee, P. H.; Lin, D. Y.; Wu, C. C.; Jeng, L. B.; Lin, Pin-Wen; Mok, K. T.; Gautam, A. M.; Zalebergg, J. R. |
